Medeon Biodesign (6499) — Cash Flow Reinvestment Rate

Latest as of March 2022: 5.77x

Medeon Biodesign (6499) has a Cash Flow Reinvestment Rate of 5.77x as of March 2022, reinvesting NT$350.52 Million (capex NT$41.12 Million plus investments NT$309.40 Million) from operating cash flow of NT$60.74 Million. Check how high is Medeon Biodesign's earnings quality to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

5.77x
(Capex + Investments) / Operating CF

Total Reinvested

NT$350.52 Million
Capex + Investments

Operating Cash Flow

NT$60.74 Million
TWD

Capital Expenditures

NT$41.12 Million
TWD

Medeon Biodesign Cash Flow Reinvestment Rate (2018–2018)

Historical reinvestment intensity for Medeon Biodesign across 1 annual periods. Explore 6499 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Medeon Biodesign (2018–2018)

Year-by-year capital reinvestment analysis for Medeon Biodesign. For live market cap and broader valuation context, see how much is Medeon Biodesign worth.

Year Reinvestment Rate Total Reinvested (TWD) Operating CF Capex YoY Change
2018 0.96x NT$310.54 Million NT$322.05 Million NT$51.14 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow